Chen L, Wang Y, Zhou H, Liang Y, Zhu F, Zhou G, et al.
Precision clinical medicine. Date of publication 2024 Jan 18;volume 7(1):pbae001.
1. Precis Clin Med. 2024 Jan 18;7(1):pbae001. doi: 10.1093/pcmedi/pbae001.
eCollection 2024 Mar.
The new insights of hyperbaric oxygen therapy: focus on inflammatory bowel
disease.
Chen L(1), Wang Y(2), Zhou H(2), Liang Y(3), Zhu F(2), Zhou G(1)(2).
Author information:
(1)Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
(2)Department of Gastroenterology, Affiliated Hospital of Jining Medical
University, Jining Medical University, Jining 272000, China.
(3)Department of Hyperbaric Oxygen, Affiliated Hospital of Jining Medical
University, Jining Medical University, Jining 272000, China.
Inflammatory bowel diseases (IBD), with an increasing incidence, pose a
significant health burden. Although there have been significant advances in the
treatment of IBD, more progress is still needed. Hyperbaric oxygen therapy
(HBOT) has been shown to treat a host of conditions such as carbon monoxide
poisoning, decompression sickness, and gas gangrene. In the last few years,
there has been an increase in research into the use of HBOT as an adjunct to
conventional treatment for IBD. Related research has shown that HBOT may exert
its therapeutic effects by decreasing oxidative stress, inhibiting mucosal
inflammation, promoting ulcer healing, influencing gut microbes, and reducing
the incidence of IBD complications. This paper aims to provide a comprehensive
review of experimental and clinical trials exploring HBOT as a supplement to IBD
treatment strategies.
© The Author(s) 2024. Published by Oxford University Press on behalf of the West
China School of Medicine & West China Hospital of Sichuan University.
DOI: 10.1093/pcmedi/pbae001
PMCID: PMC10858389
PMID: 38344218
Conflict of interest statement: The authors declare that they have no competing
interests.
